Analysts Set Viewray Inc (NASDAQ:VRAY) Price Target at $6.50
Viewray Inc (NASDAQ:VRAY) has earned an average recommendation of “Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.50.
A number of equities research analysts recently weighed in on the stock. B. Riley restated a “neutral” rating and set a $5.00 price objective (down from $9.00) on shares of Viewray in a research note on Wednesday, December 4th. ValuEngine upgraded shares of Viewray from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Guggenheim reiterated a “buy” rating and set a $8.00 price objective on shares of Viewray in a research note on Tuesday, December 3rd. Zacks Investment Research lowered Viewray from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 16th. Finally, BidaskClub lowered Viewray from a “hold” rating to a “sell” rating in a research note on Tuesday.
NASDAQ:VRAY traded up $0.20 during midday trading on Friday, reaching $3.12. 5,343,809 shares of the company traded hands, compared to its average volume of 3,428,454. Viewray has a twelve month low of $2.12 and a twelve month high of $9.76. The firm has a market capitalization of $290.27 million, a price-to-earnings ratio of -3.00 and a beta of 1.17. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.70 and a quick ratio of 2.58. The company has a fifty day moving average price of $3.99 and a 200 day moving average price of $4.52.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC acquired a new stake in shares of Viewray in the second quarter worth $348,000. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Viewray by 2.7% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 433,449 shares of the company’s stock valued at $1,257,000 after purchasing an additional 11,388 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of Viewray by 224.7% in the second quarter. Envestnet Asset Management Inc. now owns 41,009 shares of the company’s stock worth $361,000 after purchasing an additional 28,380 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Viewray in the third quarter worth approximately $121,000. Finally, Millennium Management LLC boosted its holdings in shares of Viewray by 114.7% during the third quarter. Millennium Management LLC now owns 1,549,067 shares of the company’s stock worth $4,492,000 after purchasing an additional 827,592 shares during the period.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Article: What is a short straddle?
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.